The efficacy and safety of *Clostridium butyricum* and *Bacillus coagulans* in *Helicobacter pylori* eradication treatment

An open-label, single-arm pilot study

Jian Zhang, MS<sup>a,b</sup>, Jingzhi Guo, MS<sup>c</sup>, Dan Li, MS<sup>d</sup>, Min Chen, MD<sup>a</sup>, Jie Liu, BS<sup>a</sup>, Chenchen Feng, MS<sup>d</sup>, Qi He, MS<sup>d</sup>, Jing Zhao, MD<sup>e</sup>, Luyao Zhang, MS<sup>a</sup>, Jie Chen, MS<sup>a</sup>, Yongquan Shi, MD<sup>a</sup>,∗

Abstract

**Background:** *Helicobacter pylori* (*H pylori*) infection plays a critical role in gastritis-associated diseases, gastroduodenal ulcers, and even gastric cancer. Studies have shown that probiotics may exhibit antagonistic activity against *H pylori*.

**Methods:** This study aimed to assess the efficacy and safety of monotherapy with *Clostridium butyricum* (*C butyricum*) and *Bacillus coagulans* (*B coagulans*) for *H pylori* treatment. Our research was an open-label, single-arm pilot study of *H pylori* eradication. Subjects diagnosed with *H pylori* infection as outpatients at Xijing Hospital were randomized (1:1:1) to receive 8 weeks of therapy with *C butyricum* (group A), *B coagulans* (group B), or *C butyricum* plus *B coagulans* (group C). *H pylori* status was assessed 1 to 2 weeks after treatment. The *H pylori* eradication rate according to intention-to-treat and per-protocol analyses was the primary outcome of study, and the delta over baseline score, adverse events, and compliance were the secondary outcomes. This study was registered at ClinicalTrials.gov (NCT 03857425).

**Results:** A total of 150 subjects were consecutively enrolled from February 2019 to August 2019. The ITT analysis demonstrated that the 3 groups achieved similar eradication rates (18%, 20%, and 26%, respectively, *P* = .597). The PP analysis yielded a similar result (24.3%, 26.3%, and 32.5%, respectively, *P* = .703). None of the subjects reported adverse events during treatment. The 3 groups had comparable compliance rates (74% vs 76% vs 80%, *P* > .05).

**Conclusion:** *C butyricum* and *B coagulans* may effectively inhibit *H pylori* to some extent, with rare adverse events, and thus may reduce the burden of antibiotic resistance.

**Abbreviations:** DOB = delta over baseline, *H pylori* = *Helicobacter pylori*, IL = interleukin, ITT = intention-to-treat, MALT = mucosa-associated lymphoid tissue, PP = per-protocol, PPIs = proton-pump inhibitors, UBT = urea breath test.

**Keywords:** bacillus coagulans, *Clostridium butyricum*, *Helicobacter pylori* infection, probiotics

1. **Introduction**

In 1994, *Helicobacter pylori* (*H pylori*) was classified by the International Research Agency on Cancer as a class I carcinogen of gastric carcinoma.<sup>[1]</sup> *H pylori* infection is considered an important etiological cause of gastritis-associated diseases, gastroduodenal ulcers, mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric malignant tumors.<sup>[2]</sup> The general consensus is that all patients who are diagnosed with *H pylori* infection should aim to eradicate the pathogen.<sup>[3]</sup> In the 1990s, 7- or 10-day triple therapies (proton-pump inhibitors (PPIs) with twice-daily clarithromycin and metronidazole (or amoxicillin)) achieved a satisfactory eradication rate (>90%) in clinical trials and were soon regarded as the standard triple therapy, which is still popular worldwide.<sup>[3]</sup> Unfortunately, the...
eradication rate of the standard triple therapy has decreased to below 80% in most areas of the world, mainly due to increasing resistance to clarithromycin and metronidazole.\(^{[3]}\) Hence, the latest guidelines and consensus recommend prolonging the duration of therapy from 7 or 10 days to 14 days, and bismuth-containing quadruple therapies are recommended in areas where the resistance rate to clarithromycin is more than 15%.\(^{[3,4]}\)

The increasing resistance to antibiotics is the most prominent challenge for the treatment of \(H\) \(pylori\)\(^{[3]}\) worldwide. Since their introduction 50 years ago, antibiotics have been considered miracle drugs. However, they have been overused for decades to treat viral infections or promote animal weight gain, and this overuse is responsible for the rapidly increasing resistance. Moreover, patients often withdraw from antibiotic treatment because of side effects or severe adverse events of antibiotics and too many capsules, all of which contribute to low compliance.\(^{[7]}\)

Since the gut microbiome has emerged as an essential factor in human health and disease, research has also assessed the potential role of interactions of \(H\) \(pylori\) with other microbiota in the upper and lower digestive systems.\(^{[8]}\) Probiotics have been included in \(H\) \(pylori\) eradication therapy and have been demonstrated to be useful in alleviating the side effects of traditional antibiotic therapies and enhancing patient compliance.\(^{[9]}\) A number of studies have encouragingly found that probiotics possess antagonistic activity against \(H\) \(pylori\) by reducing antibiotic side effects to improve the eradication of \(H\) \(pylori\) infection and reduce injury caused by \(H\) \(pylori\).\(^{[10,11]}\)

Therefore, we conducted the present pilot study to evaluate the efficacy and safety of probiotics alone for \(H\) \(pylori\) eradication.

2. Methods

2.1. Study design

This study was a single-center, open-label, randomized, prospective, single-arm pilot trial conducted at Xijing Hospital from February 2019 to August 2019. We obtained informed consent from all subjects prior to enrollment, and the ethics committee of Xijing Hospital approved the study. The trial was performed according to the tenets of the Declaration of Helsinki. Our study followed the recommendations of the Consolidated Standards of Reporting Trials statement for ensuring the quality of randomized controlled trials. Our study was registered at ClinicalTrials.gov (ID: NCT03857425).

2.2. Population

We consecutively enrolled patients who were diagnosed with \(H\) \(pylori\) infection as outpatients at Xijing Hospital. All subjects were recruited for our study after providing informed consent. Eligibility criteria included the following: patients aged between 18 and 75 years of either sex; patients with upper gastrointestinal symptoms and documented \(H\) \(pylori\) infection for the first time; patients who were willing to receive eradication treatment; patients who were not pregnant or nursing; if they had childbearing potential, they were required to use medically acceptable contraception for the duration of the study and 30 days thereafter. The exclusion criteria were as follows: patients who had previously used antibiotics to eradicate previously recorded \(H\) \(pylori\) infections; patients with contraindications to the study drugs; patients with substantial organ impairment or severe or unstable cardiopulmonary or endocrine disease; patients who consistently used antiulcer drugs (including PPIs within 2 weeks before the C13-urea breath test (UBT)), antibiotics or bismuth complexes (more than 3 times /mo before screening); patients who were pregnant or lactating; patients who were diagnosed with gastroduodenal ulcer and MALT lymphoma; patients who had undergone upper gastrointestinal surgery; patients with Barrett’s esophagus or highly atypical hyperplasia, with symptoms of dysphagia; patients with evidence of bleeding or iron-deficiency anemia; patients with a history of malignancy; patients with a drug or alcohol abuse history in the past year; patients who used systemic corticosteroids, nonsteroidal anti-inflammatory drugs, anticoagulants, or platelet aggregation inhibitors (except the use of aspirin at less than 100mg/d); patients enrolled in other clinical trials in the past 3 months; patients who had psychological problems or poor compliance; and patients who refused to sign the informed consent form.

2.3. \(H\) \(pylori\) detection

The status of \(H\) \(pylori\) infection was confirmed by the following: a C13/14-UBT, a rapid urease test, a stool antigen test, or histological examination and \(H\) \(pylori\) culture. \(H\) \(pylori\) infection was confirmed by positive results of at least 1 of the 4 abovementioned tests. Post-treatment \(H\) \(pylori\) eradication status was assessed by at least one of C13/14-UBT and a stool antigen test at 1 to 2 weeks after the subjects finished 8 weeks of therapy with probiotics.

2.4. Procedure

Our center has an independent research assistant, and the independent random number sequence was generated by a third party. According to the independent random number sequence, the eligible patients were randomized (1:1:1) to receive 8 weeks of \(Clostridium\) \(butyricum\) (C \(butyricum\)) capsules (350 mg \(C\) \(butyricum\) capsules BID) (group A), \(Bacillus\) \(coagulans\) (B \(coagulans\)) tablets (350 mg \(B\) \(coagulans\) tablets \(C\) \(butyricum\) capsules \(B\) \(coagulans\) tablets \(C\) \(butyricum\) capsules BID) (group B), or \(C\) \(butyricum\) capsules (350 mg \(C\) \(butyricum\) capsules BID) plus \(B\) \(coagulans\) tablets (350 mg \(B\) \(coagulans\) tablets \(C\) \(butyricum\) capsules \(B\) \(coagulans\) tablets \(C\) \(butyricum\) capsules BID) (group C). The \(C\) \(butyricum\) capsules and \(B\) \(coagulans\) tablets were both provided by Donghai Pharmaceutical Co Ltd, Shandong, China. Demographic and basic characteristics data, including age, gender, body mass index, minority, diagnosis, and other diseases, were obtained from every patient upon enrollment. Patients with gastrointestinal symptoms were prescribed PPIs, compound digestive enzymes, testa triticum tritium purif, trimetubine maleate, and hydrotalcite for 2 to 4 weeks at the beginning of the treatment. All these medicines were ceased 4 to 6 weeks before the end of probiotic treatment to avoid interference with the results of the \(H\) \(pylori\) status. We informed the subjects of the common adverse effects of drugs in the study and asked them to record their symptoms in a case report form.

We evaluated the adverse events prospectively by using a 4-point scale: none; mild (irritating discomfort that does not interfere with normal life); moderate (discomfort enough to interfere with normal life); and severe (discomfort causing the cessation of eradication treatment).

One to 2 weeks after finishing the 8-week treatment with probiotics, post-treatment \(H\) \(pylori\) infection status was confirmed by at least 1 of the 2 tests mentioned above. The subjects were asked to stop PPIs and histamine-2 blockers for at least 2 weeks before any test. The technicians who carried out the \(H\) \(pylori\) tests were blinded to the patients’ therapies.
The patients who failed to eradicate \( H \) pylori were offered standard 14-day quadruple therapy. The flow diagram of the study is summarized in Figure 1.

2.5. Outcome

The primary outcome was the \( H \) pylori eradication rate. The secondary outcome was the frequency of overall adverse events. Remnant medication of more than 20% of all medications at completion was regarded as poor compliance.

2.6. Statistical analysis

Statistical analyses were performed by using SPSS software (version 23.0, IBM, Armonk, NY). Comparisons of continuous variables were performed by Student \( t \) test or one-way ANOVA. Categorical data were compared using Fisher exact test or the \( \chi^2 \) test for contingency as appropriate. A 2-tailed \( P < .05 \) was considered statistically significant.

3. Results

3.1. Baseline data and characteristics

From February 2019 to August 2019, a total of 150 patients were eligible for the study and were enrolled. The eligible subjects were randomized to receive 8 weeks of \( C \) butyricum capsules (350 mg \times 3 capsules BID), \( B \) coagulans tablets (330 mg \times 3 tablets TID), or \( C \) butyricum capsules (350 mg \times 3 capsules BID) plus \( B \) coagulans tablets (350 mg \times 3 tablets TID). As shown in Table 1, the 3 groups had comparable baseline demographic characteristics. Twelve subjects in group A, 10 subjects in group B, and 8 subjects in group C were lost to follow-up and did not return to finish the test in time. One patient in group A, 2 patients in group B, and 2 patients in group C violated the protocol or had poor compliance. All 35 patients were regarded as having eradication failure in the intention-to-treat (ITT) analysis and were excluded from the per-protocol (PP) analysis. Twenty-six of 28 patients in group A, 27 of 28 patients in group B, and 27 of 27 in group C...
failed to achieve *H pylori* eradication and agreed to receive the standard quadruple regimen.

### 3.2. *H pylori* eradication rates

As shown in Table 2, *H pylori* eradication rates reached 18% in group A, 20% in group B, and 26% in group C in the ITT population. In the PP population, the *H pylori* eradication rates were 24.3% in group A, 26.3% in group B, and 32.5% in group C. The eradication rate of group C was slightly higher than that of groups A and B, but there was no significant difference among the 3 groups in either the ITT or PP analysis.

### 3.3. Adverse events and compliance

None of the patients in the 3 groups reported adverse events during the therapies. The 3 groups had comparable compliance rates (74% vs 76% vs 80%, *P* > .05).

### 3.4. C13-UBT delta over baseline (DOB) scores

Among the subjects with *H pylori* eradication failure, 34 subjects underwent C13-UBT before and after the treatment. We evaluated the difference in the C13-UBT DOB scores before and after treatment among these subjects. As shown in Figure 2, 20 subjects’ DOB scores decreased, while 14 subjects’ DOB scores increased. The means of DOB scores were similar before and after the treatment (*P* = .877).

### 3.5. Differences in baseline characteristics

We further evaluated differences in the baseline characteristics between the subjects with *H pylori* eradication success and those with *H pylori* eradication failure after probiotic administration. As shown in Table 3, the proportion of male subjects in the successful group was much higher than that of female subjects (*P* = .003).

### 4. Discussion

Probiotics are defined as “living microorganisms that provide beneficial effects on the host’s health when administered in adequate amounts.”[12] Because probiotic supplementation can restore microbial balance to prevent antibiotic-associated diarrhea or other adverse events, recent studies have comprehensively explored probiotics as an adjunct to standard therapies for *H pylori* treatment.[13,14] A series of studies have demonstrated the potential therapeutic effect of probiotics on several gastric diseases, such as diarrhea, chronic constipation, and irritable bowel syndrome.[13] Probiotics are capable of competing for food and binding sites,[13] producing antimicrobial substances, and immunomodulation, resulting in stabilization of the intestinal microbiome via pathogen inhibition.[15] Under these circumstances, it can be supposed that probiotics interfere with pathogens that may colonize the stomach.[16]

Several experimental studies have proposed various possible probiotic antagonistic mechanisms in *H pylori*. Some specific strains of probiotics have been found to effectively improve epithelial barrier function.[17,18] *H pylori* is thought to destroy the gastric mucosa through the expression of virulence factors, including VacA and CagA.[19] The increased production of IgA induced by probiotic strains has been demonstrated to be helpful in strengthening the mucosal barrier against pathogen invasion.[20,21] Moreover, probiotics inhibit the binding of *H pylori* to epithelial cells, and many studies have indicated that the

### Table 1

Baseline characteristics of the patients.

|            | Group A | Group B | Group C | *P* value |
|------------|---------|---------|---------|-----------|
| Age (y) (mean±s.d.) | 45.80±10.96 | 47.01±13.75 | 49.92±10.24 | .203 |
| Gender (male/female) | 21/29 | 19/31 | 17/33 | .712 |
| BMI (body mass index) | 23.01±2.86 | 22.09±2.42 | 22.71±3.02 | .245 |
| Minorities | | | | .329 |
| The Han nationality | 50 | 48 | 50 | .928 |
| Others | 0 | 2 | 0 | .912 |
| Other diseases | | | | .329 |
| Diabetes | 2 | 1 | 0 | |
| Hypertension | 2 | 1 | 2 | |
| Others | 2 | 1 | 1 | |
| Diagnosis | | | | |
| Chronic gastritis with dyspepsia | 21 | 24 | 27 | |
| Chronic erosive gastritis | 10 | 13 | 10 | |
| Chronic gastritis with constipation | 21 | 16 | 18 | |
| Asymptomatic | 4 | 3 | 4 | |

BMI=body mass index.

### Table 2

*H pylori* eradication rates.

|            | ITT analysis | PP analysis |
|------------|-------------|-------------|
| Group A    | Group B     | Group C     |
| n/N(%)     | 9/50 (18%)  | 10/50 (20%) | 13/50 (26%) |
| 95%CI      | 7%-29%      | 8.5%-31.5%  | 13.4%-38.6% |
| *P* value  | .597        | .937 (24.3%)| .937 (24.3%)|
| Group A    | Group B     | Group C     |
| n/N(%)     | 9/37 (24.3%)| 10/38 (26.3%)| 13/40 (32.5%)|
| 95%CI      | 9.8%-38.8%  | 11.6%-41.0% | 17.3%-47.7% |
| *P* value  | .709        | .937 (24.3%)| .937 (24.3%)|

*CI=confidence interval, ITT=intention-to-treat, PP=per-protocol.*
underlying mechanisms are nutrient or adhesion site competition with pathogens. Some studies have provided evidence that Lactobacillus reuteri can inhibit H pylori adhesion by competing for specific receptor binding sites, such as asialo-GMI and sulfatide. Previous colonization of germ-free mice by probiotics reduced later H pylori colonization. The ability of probiotics to compete for adhesion is one of the generally accepted mechanisms to counteract H pylori from invading the host. It is of great interest to investigate the exact molecular mechanism. In addition, probiotics can secrete antimicrobial substances to prevent H pylori colonization. Urease production helps H pylori survive in acidic environments by converting urea into ammonia and CO₂ to increase the surrounding pH. It has been reported that probiotics, such as some Lactobacilli strains, secrete antimicrobial substances that inhibit the attachment of H pylori to the epithelium. Lactic acid secreted by probiotics is observed to lower the surrounding pH and exhibit inhibitory activity against urease, making the environment unfavorable for the growth of H pylori. H pylori infection triggers inflammation, causing the release of several inflammatory mediators, such as cytokines and chemokines. Interleukin 8 (IL-8) is responsible for the secretion of neutrophils and monocytes in gastric mucosal
surfaces. The secretion of TNF-α, IL-1, and IL-6 can be stimulated by dendritic cells and monocytes. Immunomodulation is thought to be one of the crucial functions allowing probiotics to inhibit *H pylori* infection. When the pH was adjusted to 7.4, the culture supernatant of *H pylori* adjusted to 7.4, the culture supernatant of probiotics to inhibit *H pylori* eradication. [23] Gotteland et al [26] reported an eradication rate of 12% among placebo-treated subjects in previous studies. For the subjects who failed to eradicate *H pylori* without intervention, [27] Boonyaritichaikij et al [27] administered heat-killed *B coagulans* and *B brevis* plus inulin every day for 8 weeks. In the same trial, administration of *L acidophilus* 1800 million CFU daily for 10 days. Our treatment duration was 2 months, which was considered acceptable by most patients according to the study compliance rate. Only 1 subject reported serious constipation after therapy with *B coagulans*. The adverse event rate in this study was much lower than that of standard antibiotics. The results of our study confirmed that *C butyricum* and *B coagulans* can eradicate *H pylori* to some extent with satisfactory safety. Our probiotic treatment will be an ideal option for people who are not suitable for antibiotic treatment, such as children (in whom antibiotic treatment is reported to disrupt microbial homeostasis [28]), the very old, and patients with serious organ dysfunction who are intolerant to standard treatment. There were still several limitations in our study. Our study was a single-arm study. We did not include a control or placebo group. Therefore, a randomized control study is needed to further investigate the efficacy and safety of the target probiotics. Second, our subjects were mostly from northwest China. The eradication ability of *C butyricum* and *B coagulans* in other regions or countries needs to be confirmed through multicenter studies. Moreover, the duration of the regimens was based on our experience, and the dosage of the probiotics was established on the basis of the experience in prescribing medicine for intestinal diseases such as diarrhea, constipation, or inflammatory bowel disease. Therefore, further investigation on the best dosage and duration is anticipated. Last but not the least, the exact mechanisms of *C butyricum* and *B coagulans* on *H pylori* remain unclear, and we are looking forward to conducting more basic experiments on these mechanisms.

In conclusion, *C butyricum* and *B coagulans* can eradicate *H pylori* to some extent, and our study provides an alternative option for patients who are unwilling to receive standard therapies or who are intolerant to antibiotics.

### Acknowledgments

The authors thank the study participants and the clinical teams and the GCP Center of Xijing Hospital. The authors are grateful for financial support from Shaanxi Province Science and Technology.

### Author contributions

Conceptualization: Yongquan Shi, Jian Zhang.
Data curation: Jian Zhang, Jingzhi Guo, Dan Li, Qi He.
Formal analysis: Jian Zhang, Jingzhi Guo, Jing Zhao, Chenchen Feng.
Investigation: Jian Zhang, Min Chen, Jie Liu, Luyao Zhang.
Methodology: Yongquan Shi, Jian Zhang.
Project administration: Yongquan Shi, Jian Zhang.
Writing – original draft: Jian Zhang, Jie Chen.

### References

[1] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. *Schistosomes, liver flukes and *Helicobacter pylori*. IARC Monogr Eval Carcinog Risks Hum 1999;61:1–184.

[2] Suerbaum S, Michetti P. *Helicobacter pylori* infection. N Engl J Med 2002;347:1175–86.

[3] Current European concepts in the management of *Helicobacter pylori* infection. The Maastricht Consensus Report. European *Helicobacter Pylori* Study Group [published correction appears in *Gut* 1997 Aug;41(2):276]. *Gut* 1997;41:8–13.

[4] Graham DY, Fischbach L. *Helicobacter pylori* treatment in the era of increasing antibiotic resistance. *Gut* 2010;59:1143–53.
